You are here: Industry Insights > Inhibitor

News List

IL-18 inhibitor drug holds great potential for inflammatory diseases europeanpharmaceuticalreview
April 26, 2019
An international team of researchers has identified the key role that IL-18 protein plays in Still’s disease, making it a prime candidate for IL-18 inhibitor drug that is proving promising in current trials.
AACR: Bayer posts early clinical data on follow-up to Loxo's Vitrakvi fiercebiotech
April 03, 2019
Bayer has shared preliminary clinical data on the second TRK inhibitor it licensed from Loxo Oncology.
CStone received IND approval in China for HDAC6 inhibitor CS3003 en-cphi.cn
March 13, 2019
Cstone announced that the National Medical Products Administration (NMPA) recently approved company's histone deacetylase 6 (HDAC6) selective inhibitor CS3003 for Phase I clinical trial in China.
Groundbreaking Memory Research Shows Amazonian Plant Extract PTI-00703 Cat's Claw as Potent Inhibitor and Reducer of Both Brain Plaques and Tangles en-cphi.cn
March 06, 2019
Scientific Reports recently published a landmark research paper which has immediate favorable implications for brain health and memory loss in the aging brain.
Morphic and Janssen collaboratively develop integrin therapies pharmaceutical-technology
February 26, 2019
Biotechnology company Morphic Therapeutic has formed a research and collaboration alliance with Johnson & Johnson subsidiary Janssen for the discovery and development of new integrin therapeutics....
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases pharmafocusasia
December 13, 2018
Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the company’s lead candidate, RDN-929, a potent and selective HDAC-CoREST inhibitor.
GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula firstwordpharma
December 03, 2018
GlaxoSmithKline announced Monday an agreement to acquire Tesaro for around $5.1 billion in cash, gaining the latter's oral PARP inhibitor Zejula (niraparib). GlaxoSmithKline CEO Emma Walmsley said the deal "will strengthen our pharmaceuticals business by
CStone’s MEK inhibitor approved for trials in China pharmaceutical-technology
August 01, 2018
CStone Pharmaceuticals has announced its CS3006, a small molecule inhibitor of mitogen-activated protein kinase (MEK), has received investigational new drug approval for clinical trials from the China National Drug Administration (CNDA). This comes only t
Bristol-Myers posts early checkpoint combination data on fast-advancing rival to Incyte’s IDO1 inhib fiercebiotech
November 13, 2017
Bristol-Myers Squibb has posted interim data on its IDO1 inhibitor in combination with Opdivo.

Previous page 1 2 3 4 5 Next page